Carregant...
“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome
We recently found that trastuzumab benefit may be lower in a small subset of early breast cancer (BC) patients (pts) with tumors expressing high levels of both hormonal receptors (HRs), i.e. triple positive (TP). To better investigate the role of HRs in HER2 positive BC, we retrospectively identifie...
Guardat en:
Publicat a: | Oncotarget |
---|---|
Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artigo |
Idioma: | Inglês |
Publicat: |
Impact Journals LLC
2016
|
Matèries: | |
Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4951261/ https://ncbi.nlm.nih.gov/pubmed/26910921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7480 |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|